GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT00736229

CompletedPhase 4Results posted

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit

Lead sponsor

Saint Luke's Health System

Asset

Exenatide

Intravenous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Cardiovascular disease, Prediabetes / glucose intolerance

Key I/E criterion

—

Primary endpoints

•Median Glucose Values From Steady State•Steady State

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00736229

Org study ID08-206

Timeline

Milestones

Study first posted2008-08-15estimated

Last update posted2014-11-20estimated

Results first posted2014-11-20estimated

Study start2008-08 (month precision)

Primary completion2011-06actual (month precision)

Study completion2012-08actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Cardiovascular diseasePrediabetes / glucose intolerance

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Admission to coronary ICU

•Admission blood glucose 140-299 mg/dL

•Primary cardiovascular diagnosis by attending physician

•Under primary care of cardiology service

•Age > 18 years old

•Ventilator independent

•Able to provide informed consent

Exclusion criteria

•Admission blood glucose < 140 or > 300 mg/dL

•Ventilator dependent

•Unconscious sedation

•Type 1 diabetes

•Known pregnancy

•Admitted to coronary ICU for right heart cath to measure hemodynamics prior to transplant

•Post transplant procedure

•Currently enrolled in another clinical trial

•Unable to provide informed consent

•Creatinine clearance < 30 mL/min

•On insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine [Lantus®] or detemir [Levemir®])

•Gastroparesis

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Safety / tolerability / PK

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

Median Glucose Values From Steady State Through 48 Hours or Until Discharge.

Time frame:1-48 hours

descriptive, improvement

Posted result

Group	Value (median), mg/dL	95% CI
Exenatide	132	110 – 157
Moderate	127	105 – 161
Intensive	105	92 – 128

p<0.001Kruskal-Wallis

Median Glucose Values (mg/dl) after steady state were evaluated across the three groups (Exenatide,Moderate and Intensive) with a Kruskal-Wallis test.

p<0.001Wilcoxon (Mann-Whitney)

Median Glucose Values (mg/dl) after steady state were evaluated between the Exenatide and Intensive study groups using a Wilcoxon Rank Sum tests.

p0.15Wilcoxon (Mann-Whitney)

Median Glucose Values (mg/dl) after steady state were evaluated between the Exenatide and Moderate study groups using a Wilcoxon Rank Sum tests.

Primary/protocol endpoint

Time to Steady State

Time frame:Start of infusion through 48 hours or until discharge

time to event, improvement

Posted result

Group	Value (median), hours	95% CI
Exenatide	2.0	1.5 – 5.0
Moderate	12.0	7.0 – 15.0
Intensive	3.0	1.0 – 5.0

p<0.001Kruskal-Wallis

Median Time (Hrs) to steady state was evaluated across the three groups (exenatide, moderate and intensive) with a Kruskal-Wallis test.

p0.80Wilcoxon (Mann-Whitney)

Median time (hours) to steady state were evaluated between the Exenatide and Intensive study groups using a Wilcoxon Rank Sum tests.

p<0.001Wilcoxon (Mann-Whitney)

Median time (hours) to steady state were evaluated between the Exenatide and Moderate study groups using a Wilcoxon Rank Sum tests.

Safety / tolerability / PK

2 endpoints

Secondary/protocol endpoint

Rates of Hypoglycemia and Severe Hypoglycemia

Time frame:1-48 hours

Documented hypoglycemia

threshold achievement, event

componentsDocumented hypoglycemia, Severe hypoglycemia

Posted result

Group	Value (number), participants	95% CI
ExenatidePatients with at least one hypoglycemic episode	4	—
Patients with at least one severe episode	0	—
ModeratePatients with at least one hypoglycemic episode	14	—
Patients with at least one severe episode	2	—
IntensivePatients with at least one hypoglycemic episode	22	—
Patients with at least one severe episode	1	—

Secondary/protocol endpoint

Serious Adverse Events (Death, Non-fatal Myocardial Infarction, and Non-fatal Stroke Through 30 Days)

Time frame:30 days

Serious AEs (any)

composite event, event

componentsAll-cause death, Non-fatal MI, Non-fatal stroke

Posted result

Group	Value (number), participants	95% CI
Exenatide	4	—

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2013 Jan-Feb (year)PMID23186969doi:10.4158/EP12196.ORvia CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.